Locations:

Tag: BTKi inhibitors

Dr. Robert Fox against a decorative background with a podcast icon overlay

April 16, 2025/Neurosciences/Podcast

Emerging Therapeutic Options in Progressive Multiple Sclerosis (Podcast)

Long-awaited efficacy against disability progression appears to be at hand

hand pointing at brain scans on a computer monitoring

April 9, 2025/Neurosciences/Multiple Sclerosis

Disability Progression Slowed for First Time in Nonrelapsing Secondary Progressive Multiple Sclerosis

BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial

middle-aged woman leaning against porch railing

September 20, 2024/Neurosciences/Multiple Sclerosis

First Evidence of Delayed Disability Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial

23-CNR-4045267-CQD-Hero-650×450-v2 Dr Jagadeesh

September 12, 2023/Cancer/Research

Pirtobrutinib Shows Promise for Older, Heavily Pretreated Patients with CLL

Large trial shows efficacy and lower incidences of heart issues and bleeding events with novel non-covalent BTK inhibitor

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-CNR-3938585-CQD-Hero-650×450 Dr Caimi1

July 13, 2023/Cancer/Research

Increased Risk of Stroke, Bleeding and Atrial Fibrillation in Older CLL Patients Treated with Ibrutinib

Regular surveillance necessary to identify safety signals

December 9, 2019/Cancer/Research

Findings Suggest CAR T-Cell Therapy is Highly Effective for Relapsed/Refractory Mantle Cell Lymphoma

Autologous anti-CD19 agent produces impressive survival improvements

BackPage 1 of 1Next